

May 18, 2016



Pressure BioSciences, Inc. Reports First Quarter 2016 Financial Results and Provides Business Update

Quarterly Products and Services Revenue Increases 26% Year/Year; Sales of Instruments and Consumables Show Significant Increases

Q1 2016 Highlights Include Completion of Over-Subscribed \$5 Million Financing & Co-Marketing Agreement with Global Life Science Leader SCIEX

Investor Conference Call Scheduled for Wednesday, May 18, 2016 at 4:30 PM EDT

SOUTH EASTON, Mass., May 18, 2016 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: P BIO) ("PBI" or the "Company") today announced financial results for the 2016 first quarter ended March 31, 2016, provided a business update, and offered limited guidance for the remainder of FY2016.

Financial Results: Q1 2016 vs. Q1 2015. Products and services revenue was \$454,350 for the first quarter of 2016 compared to \$359,364 for same period in 2015, an increase of \$94,986 or 26%. Two major drivers of our product revenue growth were instrument sales, which increased 41% during the comparative quarterly periods (from \$234,985 to \$332,016) and consumable sales, which increased 11% (from \$39,835 to \$44,234). Grant revenue decreased 31% during the comparative periods, from \$80,770 in Q1 2015 to \$56,128 in Q1 2016. This decrease in grant revenue, which is expected to be short-term, allowed the Company to focus grant personnel in other critical areas during the first quarter of 2016, specifically sales/marketing and new product development. The additional efforts in sales/marketing were partially responsible for the 16% increase reported in quarterly total revenue, from \$440,134 in Q1 2015 to \$510,478 in Q1 2016, despite the short-term decrease in grant revenue.

Operating loss for the quarter ended March 31, 2016 was \$1,045,945 compared to a loss of \$874,819 for the same period in 2015, an increase of approximately 19.6%. This increase in operating loss was due to a large extent to increases in R&D (primarily the addition of a Ph.D. level electrical engineer and increased facility rental cost to accommodate growth), M&S expenses (primarily the costs for additional marketing and for data generation by our key collaborators), and G&A (primarily costs related to our successful fund-raising efforts), off-set partially by increases in total revenue.

Loss per common share – basic and diluted – was \$0.26 for the quarter ended March 31,

2016 compared to a loss per common share – basic and diluted – of \$0.11 for the same period in 2015.

Financial & Operational Highlights: Q1 2016

a)	Approximately \$1.4M was received in a private placement of fixed-rate convertible debentures during the quarter, bringing the total raised in our \$5M PIPE to an over-subscribed amount of \$6.3M.
b)	All five members of the Company's Board of Directors participated in the final close of the Company's \$5M PIPE, with a total investment from the directors of approximately \$165,000.
c)	Q1 2015 products & services revenue increased by approximately 26% over Q1 2015.
d)	We added a full-time, Ph.D. level electrical engineer to our R&D staff.
e)	SCIEX, a global leader in life science analytical technologies, and a wholly-owned subsidiary of the Danaher Corporation, announced that they and PBI had entered into an exclusive co-marketing agreement.
f)	In a report focused on the exclusive co-marketing agreement between SCIEX and PBI, Emerging Growth LLC indicated the combination of the two companies' technologies could result in superior biological insights and discoveries, and in rapid and dramatic revenue growth for PBI.
g)	SCIEX and Children's Medical Research Center (Sydney, Australia) announced they had joined forces to advance the promise of precision medicine. The partners stated they would benefit from SCIEX's exclusive collaborators, including PBI, and from PBI's PCT platform for increased protein quantitation and reproducibility.
h)	PBI participated in a SCIEX workshop on new innovations towards industrialized proteomics at the US HUPO scientific conference in Boston (March 2016), marking the first time the two companies had presented together under their co-marketing agreement.
i)	We completed the build of the initial working model ("breadboard") of the new Barocycler 2320EXTREME, designed primarily for use in mass spectrometry protein sample preparation, including PCT-SWATH. We also came to an arrangement with a local ISO-certified contract manufacturer, purchased sufficient parts for 30 complete units, and started the build of the first true prototype unit.

Near-Term Goals: Q2-Q4 2016

a)	Continue to implement a sound path toward financial self-sufficiency and future growth and profitability.
b)	Increase total, products & services, and grant revenues, as well as gross margins, quarter/quarter and year/year.
c)	Complete the manufacture of the Barocyler 2320 EXTREME and begin the commercialization phase for this robust, computer-driven, highly capable new pressure-generating instrument during Q2 2016.
d)	Support and expand our co-marketing program with SCIEX.
e)	Secure a strategic marketing and distribution partner for the Barozyme HT48 high throughput system and for the NMR and EPR PCT-based sample preparation systems.
f)	Implement an expanded marketing campaign for the patent-pending micro-Pestle consumable.
g)	Expand sales and marketing capabilities to reach into new countries, investigators, and fields-of-use.
h)	Continue to prepare for a targeted up-list to NASDAQ or the NYSEMKT.

Mr. Richard T. Schumacher, President and CEO of PBI, commented: "We believe the market for our pressure-based products (instruments and consumables) is large, diverse, and growing. In order to successfully increase and expand our penetration into this market, it is essential that we continue to increase market exposure and acceptance of our novel PCT-based product line. We believe the major operational accomplishments of the 2016 first quarter – especially the co-marketing agreement with SCIEX and the development of the new Barocyler 2320EXTREME – will play key roles in increasing our visibility, acceptance, and success in penetrating this market, which will subsequently help PBI achieve rapid and dramatic growth in the near future."

Mr. Jeffrey N. Peterson, Chairman of PBI, added: "We are very pleased to have completed critical operational objectives in strategic marketing, new product development, and manufacturing during the first quarter of 2016, especially with the simultaneous achievement of key financial objectives. We believe that 2016 is a watershed year for PBI, and are delighted to be presenting the Company with a dramatically improved financial position, growing recognition from both the investment and scientific communities, and a well-defined path towards our planned up-listing to a major stock exchange."

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated \$6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary development and sales efforts are in the biomarker discovery, drug discovery and design, and forensics areas. Customers also use our products in other areas, such as bio-therapeutics characterization, soil & plant biology, vaccine development, and counter-bioterror applications.

Earnings Call

The Company will hold an Earnings Conference Call at 4:30 PM EDT on Wednesday, May 18, 2016. To attend this teleconference via telephone, Dial-in: (877) 407-8031 (North America), (201) 689-8031 (International). Verbal Passcode: PBI Q1 2016 Financial Conference Call, ID 13637901. Replay Number (877) 660-6853 (North America); (201) 612-7415 (International). Teleconference Replay Available for 30 days.

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. The Company's financial results for the quarter ended March 31, 2016 may not necessarily be indicative of future results. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:

<http://www.pressurebiosciences.com>

Please visit us on Facebook, LinkedIn, and Twitter.

PRESSURE BIOSCIENCES, INC. AND SUBSIDIARY
CONSOLIDATED BALANCE SHEETS

(UNAUDITED) (AUDITED)

**March 31,
2016**

December 31, 2015

ASSETS

CURRENT ASSETS

Cash and cash equivalents	\$93,387	\$ 116,783
Accounts receivable	393,911	113,256
Inventories, net of \$50,000 reserve at March 31, 2016 and December 31, 2015	966,549	1,038,371
Prepaid income taxes	7,381	7,381
Prepaid expenses and other current assets	337,505	213,926
Total current assets	1,798,733	1,489,717
Investment in available-for-sale equity securities	154,824	294,522
Property and equipment, net	13,951	20,149
TOTAL ASSETS	\$1,967,508	\$ 1,804,388

LIABILITIES AND STOCKHOLDERS' DEFICIT

CURRENT LIABILITIES

Accounts payable	\$780,136	\$ 941,389
Accrued employee compensation	214,119	176,009
Accrued professional fees and other	645,003	821,088
Deferred revenue	207,129	140,878
Convertible debt, net of debt discount of \$0 at March 31, 2016 and December 31, 2015	100,000	100,000
Other debt, net of discount of \$2,499 and \$3,041, respectively	238,979	151,628
Warrant derivative liability	5,571,000	3,295,976
Conversion option liability	7,028,206	3,940,791
Total current liabilities	14,784,572	9,567,759

LONG TERM LIABILITIES

Related party convertible debt, net of debt discount of \$288,930 and \$0, respectively	2,074	-
Convertible debt, net of debt discount of \$5,655,498 and \$5,223,658, respectively	1,005,002	177,342
Deferred revenue	36,935	36,935
TOTAL LIABILITIES	15,828,583	9,782,036

STOCKHOLDERS' DEFICIT

Series D Convertible Preferred Stock, \$.01 par value; 850 shares authorized; 300 shares issued and outstanding on March 31, 2016 and December 31, 2015, respectively (Liquidation value of \$300,000)	3	3
Series G Convertible Preferred Stock, \$.01 par value; 240,000 shares authorized; 86,570 shares issued and outstanding on March 31, 2016 and December 31, 2015, respectively	866	866
Series H Convertible Preferred Stock, \$.01 par value; 10,000 shares authorized; 10,000 shares issued and outstanding on March 31, 2016 and December 31, 2015, respectively	100	100
Series H2 Convertible Preferred Stock, \$.01 par value; 21 shares authorized; 21 shares issued and outstanding on March 31, 2016 and December 31, 2015, respectively	-	-
Series J Convertible Preferred Stock, \$.01 par value; 6,250 shares authorized; 3,546 shares issued and outstanding on March 31, 2016 and December 31, 2015, respectively	36	36
Series K Convertible Preferred Stock, \$.01 par value; 15,000 shares authorized; 11,416 shares issued and outstanding on March 31, 2016 and December 31, 2015, respectively	114	114
Common stock, \$.01 par value; 100,000,000 shares authorized; 23,309,898 and 23,004,898 shares issued and outstanding on March 31, 2016 and December 31, 2015, respectively	233,100	230,050
Warrants to acquire common stock	5,416,681	5,416,681
Additional paid-in capital	26,240,345	26,036,733

Accumulated other comprehensive income	(244,723)	(105,025)
Accumulated deficit	(45,507,597)	(39,557,206)
Total stockholders' deficit	(13,861,075)	(7,977,648)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	\$1,967,508	\$ 1,804,388

PRESSURE BIOSCIENCES, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)

	For the Three Months Ended March 31,	
	2016	2015
Revenue:		
Products, services, other	\$454,350	\$359,364
Grant revenue	56,128	80,770
Total revenue	510,478	440,134
Costs and expenses:		
Cost of products and services	221,699	190,783

Research and development	335,270	231,923
Selling and marketing	191,236	166,223
General and administrative	808,218	726,024
Total operating costs and expenses	1,556,423	1,314,953
Operating loss	(1,045,945)	(874,819)
Other (expense) income:		
Interest expense, net	(835,144)	(605,585)
Other expense	(912)	(36,913)
Change in fair value of derivative liabilities	(4,068,390)	(530,138)
Total other (expense) income	(4,904,446)	(1,172,636)
Net loss	(5,950,391)	(2,047,455)
Accrued dividends on convertible preferred stock	-	(16,668)
Net loss applicable to common shareholders	\$(5,950,391)	\$(2,064,123)
Net loss per share attributable to common stockholders - basic and diluted	\$(0.26)	\$(0.11)
Weighted average common stock shares outstanding used in the basic and diluted net loss per share calculation	23,198,360	18,840,390

Investor Contacts:	
Richard T. Schumacher, President & CEO	(508) 230-1828 (T)
Jeffrey N. Peterson, Chairman of the Board	(650) 812-8121 (T)

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/pressure-biosciences-inc-reports-first-quarter-2016-financial-results-and-provides-business-update-300270952.html>

SOURCE Pressure BioSciences, Inc.